Every Form 4 that Structure Therapeutics Inc. American (GPCR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GPCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPCR filings page.
Structure Therapeutics Inc. (GPCR) reported that its Chief Scientific Officer, Xichen Lin, exercised options for 17,817 Ordinary Shares at an exercise price of $0.34 per share on September 1, 2026, leaving 125,081 Ordinary Shares subject to the option.
The 17,817 Ordinary Shares were converted into 5,939 American Depositary Shares (ADSs), each ADS representing three Ordinary Shares, and all 5,939 ADSs were sold in multiple transactions at weighted average prices of $45.8642 and $47.2030 per ADS. The ADS sales were made under a Rule 10b5-1 trading plan entered into on March 26, 2026.
Structure Therapeutics Inc. (GPCR) reported insider activity by Chief Scientific Officer Xichen Lin involving option exercises, ADS conversions, and sales on 2026-08-18. Lin exercised options for 11,817 Ordinary Shares at $0.34 per share, which were converted into 3,939 American Depositary Shares (ADSs). All 3,939 ADSs were then sold in three tranches at weighted average prices of $53.133, $54.197, and $55.05 per ADS under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following the partial exercise, 142,898 Ordinary Shares remain subject to the option.
Structure Therapeutics Chief Commercial Officer John Joseph Berrios received equity awards on 2026-08-06. He was granted 174,612 share options with an exercise price of 17.54 per Ordinary Share, expiring 2036-08-05, plus 140,766 restricted share units. The RSUs vest one-fourth annually from August 6, 2026, and the options vest one-fourth on that date and in thirty-six equal monthly installments thereafter, in each case subject to his continued service. Each Ordinary Share may be represented by an ADS, with each ADS representing three Ordinary Shares.
Structure Therapeutics chief scientific officer Xichen Lin exercised options for 11,817 Ordinary Shares at $0.34 per share on August 4, 2026, converted them into 3,939 American Depositary Shares, and sold all ADS in two trades at weighted average prices of $49.2857 and $50.0290 pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026. Following this partial exercise, a share option over 154,715 Ordinary Shares remains outstanding.
FMR LLC, a more than 10% owner of Structure Therapeutics Inc., reported indirect sales totaling 17,452 American Depositary Shares on July 22, 2026, in open-market or private transactions at a weighted average $50.07 per ADS via F-Prime funds. Each ADS represents three ordinary shares. FMR and related persons continue to report large indirect holdings, including positions tied to 4,546,674 ordinary shares, and disclaim beneficial ownership of the reported securities.
Structure Therapeutics Inc. chief scientific officer Xichen Lin exercised share options covering 23,634 Ordinary Shares at $0.34 per share, converted them into 7,878 American Depositary Shares, and sold all 7,878 ADS at weighted average prices of $50.7956 and $51.7088 per ADS under a Rule 10b5-1 trading plan entered into on March 26, 2026. Following these transactions, Lin holds 228,960 Ordinary Shares directly and options over 166,532 Ordinary Shares exercisable at $0.34 per share until September 10, 2029.
Structure Therapeutics Inc.’s Chief Scientific Officer, Xichen Lin, reported an exercise-and-sale transaction involving American Depositary Shares (ADS) tied to the company’s Ordinary Shares.
Lin exercised share options for 23,634 Ordinary Shares at $0.34 per share, which were converted into 7,878 ADS and then sold at $49.0792 per ADS under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Lin holds 228,960 Ordinary Shares directly and retains share options covering 190,166 additional Ordinary Shares.
Structure Therapeutics Inc. director Russell Angus C. received a grant of options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over 12 months after June 17, 2026 and will be fully vested before the 2027 annual shareholder meeting. Following this award, he holds 39,453 derivative securities, which expire on June 16, 2036.
Structure Therapeutics Inc. director Ted W. Love received a grant of share options, giving him the right to buy 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share, set at the fair market value on the grant date.
The options vest in equal monthly installments over the 12 months following June 17, 2026 and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. director Joanne Waldstreicher received a grant of options to buy 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over 12 months following June 17, 2026 and will be fully vested before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics director Eric Dobmeier received a new stock option grant covering 39,453 Ordinary Shares. The option has an exercise price of $15.00 per share, set at the fair market value on the grant date based on the trading price of the company’s American Depositary Shares (ADSs).
The option vests in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested no later than immediately before the company’s 2027 annual shareholder meeting. The option expires on June 16, 2036. Each ADS represents three Ordinary Shares. Following this grant, Dobmeier holds 39,453 options directly.
Structure Therapeutics Inc. director Sharon Tetlow received a grant of options covering 39,453 Ordinary Shares. The options have an exercise price of $15.00 per share and expire on June 16, 2036. These options vest in equal monthly installments over the 12 months following June 17, 2026, and will be fully vested immediately before the company’s 2027 annual shareholder meeting. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. director Daniel G. Welch received a grant of share options covering 39,453 Ordinary Shares at an exercise price of $15.00 per share. The options vest in equal monthly installments over the 12 months following June 17, 2026, and will in any case be fully vested immediately before the company’s 2027 annual shareholder meeting. Following this grant, Welch holds 39,453 share options directly, each relating to Ordinary Shares that may be represented by American Depositary Shares, with each ADS representing three Ordinary Shares.
Structure Therapeutics Inc. reported that its COO & GC, Matthew Lang, received new equity compensation awards. He was granted 184,614 restricted stock units, each representing one Ordinary Share, which vest in four equal annual installments starting on April 15, 2026, subject to his continued service. He also received a stock option for 223,776 Ordinary Shares at an exercise price of 18.08 per share, expiring on April 14, 2036. One-quarter of the option vests on the first anniversary of April 15, 2026, with the remainder vesting in 36 equal monthly installments, conditioned on continued service. The filing notes that each American Depositary Share represents three Ordinary Shares.
FMR LLC, a ten percent owner of Structure Therapeutics Inc., reported open-market sales of American Depositary Shares (ADSs) of GPCR. Funds associated with FMR LLC sold 1,367 ADSs and 16,085 ADSs on April 14, 2026 at a weighted average price of $55.07 per ADS in separate transactions.
Each ADS represents three ordinary shares of Structure Therapeutics. After these sales, F-Prime Capital Partners Life Sciences Advisors Fund VI LP held 2,736 ADSs, and F-Prime Capital Partners Life Sciences Fund VI LP held 32,171 ADSs. A larger indirect position remains through ADSs representing 4,546,674 underlying ordinary shares.
Structure Therapeutics Inc. Chief Development Officer Ashley Hall reported compensation-related equity grants. Hall received an option to buy 59,073 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036, and now holds 59,073 derivative shares from this grant.
Hall was also awarded 47,706 restricted stock units, each representing one ordinary share, bringing direct ordinary share holdings to 155,187 shares after the award. The RSUs vest 1/4 each year on the anniversaries of March 1, 2026, while the option vests 1/4 on March 1, 2027 and monthly thereafter, subject to continued service.
Structure Therapeutics Inc. reported that Chief Medical Officer Blas Coll Crespo received equity compensation on March 19, 2026. He was granted an employee stock option for 93,984 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036.
He also received 75,897 Restricted Stock Units, each representing one Ordinary Share, vesting in four equal annual installments starting March 1, 2026, subject to continued service. Following these grants, he directly owns 280,878 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief technology officer Yingli Ma reported equity compensation grants rather than market trades. Ma received an option to buy 40,278 Ordinary Shares at an exercise price of $16.82 per share, expiring in 2036, and 32,526 restricted stock units representing Ordinary Shares. The RSUs vest in four annual installments starting March 1, 2026, while the option vests 25% on March 1, 2027, with the remainder vesting monthly over three years. After the RSU grant, Ma directly holds 139,917 Ordinary Shares. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. reported that Chief Scientific Officer Xichen Lin received new equity awards. Lin was granted an employee stock option for 53,703 ordinary shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these option shares will vest on March 1, 2027, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Lin was also awarded 43,368 restricted stock units, each representing one ordinary share. These RSUs vest one quarter annually on each anniversary of March 1, 2026, subject to continued service. Following the RSU grant, Lin directly holds 228,960 ordinary shares. The company notes that each American Depositary Share represents three ordinary shares.
Structure Therapeutics Inc. chief financial officer Yoon Jun reported receiving new equity compensation awards. He was granted employee stock options for 128,892 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036. One quarter of these options vest on March 1, 2027, with the remainder vesting in 36 monthly installments thereafter.
He also received 104,085 restricted stock units, each representing one Ordinary Share, vesting in four equal annual installments starting on March 1, 2026, subject to continued service. Following these awards, he held 1,401,656 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through The Yoon Family Trust. The company’s Ordinary Shares may also be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.’s CEO, Raymond C. Stevens, received new equity awards. On March 19, 2026, he was granted an option to buy 322,230 Ordinary Shares at an exercise price of $16.82 per share, expiring on March 18, 2036.
He also received 260,217 restricted stock units, each representing one Ordinary Share, vesting one-quarter annually on each anniversary of March 1, 2026, subject to continued service. Following these grants, he holds 1,401,593 Ordinary Shares directly and 1,554,586 Ordinary Shares indirectly through the Stevens 2001 Revocable Trust. Each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief medical officer Coll Crespo Blas reported a Form 4 showing a tax-related share disposition. On the vesting of a restricted share unit award, 11,826 Ordinary Shares were withheld by the company at $20.99 per share to cover income tax obligations. After this withholding transaction, Blas directly owned 204,981 Ordinary Shares. The footnotes explain that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award. On this transaction date, 11,313 Ordinary Shares were withheld by the company at a price of $20.99 per share to cover income tax obligations. After this tax-withholding disposition, Ma Yingli directly owned 107,391 Ordinary Shares. The company notes that each American Depositary Share represents three Ordinary Shares.
Structure Therapeutics Inc. chief scientific officer Xichen Lin reported a routine tax-related share transaction. On March 3, 2026, Lin had 18,735 Ordinary Shares withheld at $20.99 per share to cover income taxes triggered by the vesting of a restricted share unit award.
After this tax-withholding disposition, Lin directly owned 185,592 Ordinary Shares. The company notes that each American Depositary Share (ADS) represents three Ordinary Shares.
Structure Therapeutics Inc. reported an insider equity transaction by its Chief Financial Officer, Yoon JunMarch 3, 2026, 22,305 Ordinary Shares were disposed of through shares withheld by the company to cover income tax obligations tied to the vesting of a restricted share unit award at $20.99 per share, a tax-withholding disposition rather than an open-market sale. Following this, Yoon Jun directly held 1,297,571 Ordinary Shares and indirectly held 1,554,586 Ordinary Shares through The Yoon Family Trust. The company notes that its Ordinary Shares may be represented by ADSs, with each ADS equal to three Ordinary Shares.
Structure Therapeutics Inc.'s Chief Development Officer Ashley Hall reported several routine share movements. On March 3, 2026, Hall disposed of 4,836 Ordinary Shares at $20.99 per share to cover income taxes on a vesting restricted share unit award, leaving 107,481 Ordinary Shares directly owned.
Earlier, Hall acquired 225 American Depositary Shares (ADSs) on May 20, 2025 and 237 ADSs on November 20, 2025 through the company’s Employee Share Purchase Plan. Each ADS represents three Ordinary Shares and is convertible into Ordinary Shares at any time with no expiration date.
Structure Therapeutics Inc. CEO Raymond C. Stevens reported mixed share movements related primarily to tax withholding and existing holdings. On March 3, 2026, 53,454 Ordinary Shares were disposed of at $20.99 per share, withheld by the company to satisfy income tax obligations tied to a restricted share unit vesting.
After this tax-withholding disposition, Stevens directly held 1,141,376 Ordinary Shares. Indirectly, 1,554,586 Ordinary Shares and 12,000 American Depositary Shares (ADSs) are held by the Stevens 2001 Revocable Trust, where Raymond Stevens and Vivian Urena-Stevens act as co-trustees.
The filing also notes an earlier non-cash acquisition on November 20, 2025, when Stevens was granted 824 ADSs at $0.0000 per ADS under the company’s Employee Share Purchase Plan, bringing that direct ADS position to 1,824 ADSs. Each ADS represents three Ordinary Shares and has no expiration date.
FMR LLC, a 10% owner of Structure Therapeutics Inc. (GPCR), reported several sales of American Depositary Shares on January 15, 2026 through affiliated F-Prime funds. The trades, coded as open-market sales, included transactions such as 465 ADS at $82.10, 330 ADS at $83.35, 552 ADS at $84.22 and 20 ADS at $85.04 for F-Prime Capital Partners Life Sciences Advisors Fund VI LP, and larger blocks like 5,477 ADS at $82.10, 3,880 ADS at $83.35, 6,498 ADS at $84.22 and 230 ADS at $85.04 for F-Prime Capital Partners Life Sciences Fund VI LP.
After these trades, affiliated persons and entities whose holdings are reported by FMR LLC still held 4,546,674 ADS, while the two F-Prime funds held 5,005 ADS and 58,864 ADS, respectively. Each ADS represents three ordinary shares of Structure Therapeutics. The filing notes these positions are reported indirectly and includes a disclaimer that the reporting parties are not admitting beneficial ownership of the securities.
Structure Therapeutics insider transaction: Reporting person Ashley Hall, identified as Chief Development Officer and a director, had 6,021 ordinary shares withheld to satisfy income tax obligations related to the vesting of restricted share units on 09/18/2025. The shares were recorded at a price of $7.7433 per share and reduced Hall's beneficial ownership to 112,317 ordinary shares. The filing notes that the issuer's ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares. This appears to be a routine tax-withholding disposition following equity vesting rather than an open-market sale.
Coll Crespo Blas, Chief Medical Officer of Structure Therapeutics Inc. (GPCR), reported a change in beneficial ownership for ordinary shares on 09/18/2025. The filing shows 8,106 ordinary shares were disposed (D) at a reported price of $7.7433 per share. After the transaction the reporting person beneficially owned 216,807 ordinary shares. The filing explains the 8,106 shares represent shares withheld by the issuer to satisfy income tax obligations related to the vesting of a restricted share unit award. The form notes that the issuer’s ordinary shares may be represented by ADSs, with each ADS equal to three ordinary shares.